Catalent Expanding in Bloomington
New Jersey-based Catalent Inc. (NYSE: CTLT) has announced plans to grow its Bloomington operations. The company says it will invest nearly $14 million to expand its biologics packaging capacity at its Monroe County manufacturing facility and create 36 jobs.
Catalent entered the Bloomington market in 2017 with its $950 million acquisition of Cook Pharmica. The company says it will construct a 15,000-square-foot addition that will include five new packaging suites and a new quality control laboratory.
Construction is expected to be complete in February and Catalent says the installation and commissioning of new equipment will be phased in throughout 2017. The company says the expansion augments its existing capabilities while meeting the flexibility requirements for current and future market demand.
"This significant investment is due in a large part to Catalent’s extensive expertise in helping customers successfully navigate all stages of development and gain commercial approval for their drug products," Cory Lewis, vice president and general manager of the Catalent Biologics Drug Product business. "The packaging expansion will further enhance our comprehensive end-to-end offering for clinical and commercial customers, complementing the services that Catalent Biologics provides, including cell line development, biologics analytical, biomanufacturing, antibody-drug conjugate development, drug product fill/finish, and clinical supply services."
Catalent employs 900 at the Bloomington facility. The company says the site recently received regulatory approval for its 20th commercial product.